Abstract 812P
Background
Gynecological cancer in women may have negative mental and societal consequences impacting not only patients, but also their family members. The impact may differ between families afflicted by cervical and endometrial cancer, as the two cancers develop at different ages (median age at diagnosis 49 vs. 60 years, respectively), and is not well understood. We assessed the health and education status of family members to a woman with cervical or endometrial cancer, to elucidate potential mental and socioeconomic consequences in these.
Methods
We performed a population-based nested case-control study in Sweden, identifying 11,602 cases of cervical cancer and 34,007 cases of endometrial cancer diagnosed during 1991-2016. Each cancer case was matched with five healthy controls randomly selected from the population with same birth year. Their children and respective co-parents were identified through the Swedish multi-generation register and mental health and educational outcomes traced through the Swedish Patient Register and Statistics Sweden. A comprehensive set of mental disorders of co-parents and children and attained highest level of education of the children after mother’s diagnosis, were assessed.
Results
Co-parents and children of cervical cancer patients had 30-40% increased risk of mental disorders after women’s cancer diagnosis compared to relatives of healthy controls. The increase among children emerged right after cancer diagnosis (OR=1.32, 95%CI=1.05-1.65), whereas among the co-parents emerged from 2 years after (OR=1.42, 95%CI=1.02-1.98). For endometrial cancer, the association was present but weaker. Children aged 0-18 at mothers’ cervical cancer diagnosis were less likely to reach a higher level of education as compared to children to women without cervical cancer (OR 0.87, 95%CI 0.83-0.91). The corresponding educational impact on children of women with endometrial cancer was inconclusive.
Conclusions
Children and co-parents of women with cervical or endometrial cancer are affected adversely mentally after the cancer diagnosis, and children to mothers with cervical cancer display a generational impact in terms of lower education attainment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Karolinska Institutet.
Funding
MSD Sweden.
Disclosure
K. Sundström: Financial Interests, Institutional, Research Funding: Merck. G. Bencina, M. Andersson, S. Salomonsson: Financial Interests, Personal, Full or part-time Employment: MSD. J. Wang: Financial Interests, Institutional, Funding: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
748P - Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Presenter: Emeline Colombo
Session: Poster session 11
750P - PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Presenter: Brian Slomovitz
Session: Poster session 11
751P - Patients with endometrial cancer: Expectations and understanding of genetic counseling and hereditary carcinomas - First results of an international NOGGO/GCIG/ENGOT survey (EXPRESSION XI/IMPROVE)
Presenter: Jalid Sehouli
Session: Poster session 11
752P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Olivia Le Saux
Session: Poster session 11
753P - IN10018 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC): A single-arm, phase Ib clinical trial
Presenter: Lingying Wu
Session: Poster session 11
754P - Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
Presenter: Roisin O'Cearbhaill
Session: Poster session 11
755P - Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
Presenter: Dominique Berton-Rigaud
Session: Poster session 11
756P - First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Presenter: Gottfried Konecny
Session: Poster session 11
757P - The efficacy and safety of recombinant human adenovirus type 5 (H101) intra-tumor therapy in patients with recurrent or metastatic cervical cancer: A prospective, open-label, single-arm study
Presenter: Qiying Zhang
Session: Poster session 11